pulmonary disease
Conditions
Interventions
Experimental Group (Group O):Oliceridine:Oxalidine 0.02mg/kg was administered followed by remimazolam 0.3 mg/kg
Control group (Group S) :sufentanil :Sufentanil 0.1ug/kg was administered followed by remimazolam 0.3 mg/kg
Sponsors
Qiannan People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Painless fiberoptic bronchoscopy is planned to be performed; 2. Patients of any gender, aged 65 to 80, who can understand and sign the informed consent form; 3.ASA classification grades I - III; 4. No cognitive impairment, mental abnormality or communication disorder; 5. No participation in other clinical studies was conducted within the three months prior to inclusion.
Exclusion criteria
Exclusion criteria: 1.Severe liver and kidney dysfunction, hemostatic dysfunction, and satiety or gastrointestinal obstruction accompanied by retention of gastric contents; 2. Uncontrolled and potentially life-threatening circulatory and respiratory diseases (such as acute coronary syndrome, uncontrolled severe hypertension, severe arrhythmia, severe heart failure, recently occurred acute myocardial infarction, and acute asthma attacks, etc.); 3. Patients with mental abnormalities who are unable to understand the relevant content informed; 4. Those with severe difficult airways (Modified Markov Scale grade IV); 5. Those who are allergic to or have contraindications to the drugs used in this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough and body movement score; | — |
Secondary
| Measure | Time frame |
|---|---|
| HR,MAP,SPO2;Increase the dosage of sedatives;The number of endoscopic interruptions;Postoperative QoR-15 scale score;The frequency of pressurized oxygen supply;standing time of PACU;Adverse events (dizziness, nausea, vomiting, etc.); | — |
Countries
China
Contacts
Public ContactKuiquan Ji
Qiannan People's Hospital
Outcome results
None listed